Oxygen Biotherapeutics' common stock approved for secondary listing on SIX Swiss Exchange

Download PDF Copy

Jun 21 2010

Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) announced today that its common stock has been approved for secondary listing on the SIX Swiss Exchange in addition to its listing on the NASDAQ Capital Market. Bank am Bellevue of Zurich is acting as the company's listing agent.

"Broadening awareness of our company and making trading in our stock more accessible to our existing and potential shareholder bases were important considerations when we decided to list on the SIX," said Company Chairman and CEO Chris J. Stern. "While this listing took place by way of introduction with no new capital raised at this point, I believe it offers us access to a larger capital market, particularly in Europe."

Trading on the SIX for Oxygen Biotherapeutics' common stock is expected to begin on June 29, 2010. An announcement will be made signaling initiation of trading on the day it begins.

SOURCE Oxygen Biotherapeutics, Inc.

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

Nudibranchs (sea slugs) emerge as a promising source of cancer drugs

Wearable health trackers reveal how accurate your smartwatch really is

Curcumin activates SIRT3 to protect bone structure in diabetic mice

Muscle-derived vesicles heal damaged cells and reverse disease in new study

Omega-3 supplements lower heart rate in male athletes

Eating over 60g of almonds a day may protect DNA and cut oxidative damage

Conch shell blowing lowers apnea events during REM sleep

Methylene blue emerges as an adjunct in septic shock

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.